Helix BioPharma Corp. (TSX: “HBP”) (“Helix” or the “Company), a clinical-stage biopharmaceutical company developing unique therapies in the field of immune-oncology, based on its proprietary technological platform DOS47, is pleased to announce that Mr. Praveen Varshney has been appointed as Chief Financial Officer (CFO) and Corporate Secretary.
- 0 Comments
- FY2024